Cannabidiol: A New Hope for Patients With Dravet or Lennox-Gastaut Syndromes.

Jeffrey W ChenLaura M BorgeltAllison B Blackmer

Published in: The Annals of pharmacotherapy (2019)

This is the first cannabis-derived medication with approval from the US Food and Drug Administration. This CBD formulation significantly reduces seizures as an adjunct to standard antiepileptic therapies in patients ≥2 years old with DS and LGS and is well tolerated.

Keyphrases

drug administration
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
healthcare
drug delivery
prognostic factors
emergency department
risk assessment
patient reported outcomes
climate change
adverse drug
human health
electronic health record